Alzheimer's and Dementia: Translational Research and Clinical Interventions
ESCI-ISI SCOPUS (SonsInc.)
2352-8737
Mỹ
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)
Các bài báo tiêu biểu
Inflammation as a central mechanism in Alzheimer's diseaseAbstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the br... ... hiện toàn bộ
Tập 4 Số 1 - Trang 575-590 - 2018
Alzheimer's disease drug development pipeline: 2018Abstract Introduction Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III.Results There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on hiện toàn bộ
Tập 4 Số 1 - Trang 195-214 - 2018
Alzheimer's disease drug development pipeline: 2017Abstract Introduction There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. Methods We assessed the agents in the AD pipeline as documented in hiện toàn bộ
Tập 3 Số 3 - Trang 367-384 - 2017
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain healthAbstract Cognitive decline leading to dementia represents a global health burden. In the absence of targeted pharmacotherapy, lifestyle approaches remain the best option for slowing the onset of dementia. However, older adults spend very little time doing moderate to vigorous exercise and spend a majority of time in sedentary behavior. Sedentary behavior has been li... ... hiện toàn bộ
Tập 3 Số 3 - Trang 291-300 - 2017
Amyloid‐associated increases in longitudinal report of subjective cognitive complaintsAbstract Introduction To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden. Methods Two hundred seventy‐ni...
Tập 4 - Trang 444-449 - 2018
Accelerating drug development for Alzheimer's disease through the use of data standardsAbstract Introduction The exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data standards allow for proper integrat...
Tập 3 - Trang 273-283 - 2017
Online study partner‐reported cognitive decline in the Brain Health RegistryAbstract Introduction Methods for efficiently identifying cognitive decline and Alzheimer's disease (AD) are a critical unmet need. The goal of this work was to validate novel online study partner (SP)‐reported outcomes to identify cognitive decline in older adults. Methods ... hiện toàn bộ
Tập 4 - Trang 565-574 - 2018
Machine learning models to predict onset of dementia: A label learning approachAbstract Introduction The study objective was to build a machine learning model to predict incident mild cognitive impairment, Alzheimer's Disease, and related dementias from structured data using administrative and electronic health record sources. Methods A cohort of pat...
Tập 5 - Trang 918-925 - 2019
Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal imagesAbstract Introduction This study investigates the relationship between retinal image features and β‐amyloid (Aβ) burden in the brain with the aim of developing a noninvasive method to predict the deposition of Aβ in the brain of patients with Alzheimer's disease. Methods R...
Tập 5 - Trang 610-617 - 2019
An 8‐week, open‐label, dose‐finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutationsAbstract Introduction Frontotemporal lobar degeneration–causing mutations in the progranulin (GRN ) gene reduce progranulin protein (PGRN) levels, suggesting that restoring PGRN in mutation carriers may be therapeutic. Nimodipine, a Food and Drug Administration–approved blood‐brain barrier‐penetrant calcium...
Tập 3 - Trang 507-512 - 2017